NCT03071133 | Study Connect

Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Please Log In/Join Now first, and then use this function!

Active, Not Recruiting

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy - AI443-144

Updated: 28 May, 2019 | ClinicalTrials.gov

About This Trial
Key Eligibility Criteria

Print Friendly Summary

CONSIDERING THIS TRIAL?

Print this page and the trial guide to help you talk with your doctor.

Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Print this page AI443-144

Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

Gender(s)
N/A

Age Range
Active, Not Recruiting

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Key Eligibility Criteria

Inclusion Criteria: - Patients who are initiating the treatment with DCV Trio therapy under the approved indications, dosage, and administration Exclusion Criteria: - Patients who use the DCV Trio off label

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com